As price pressure intensifies in crowded therapy areas, healthcare systems are increasingly reliant on the introduction of generics and biosimilars in order to reduce spending. In this research, we test if physicians’ price sensitivity is sufficient to drive cost reductions alone, or if payer-led controls and guidelines must be implemented to effect this change.
The science of credibility: Communicating complex science to diverse stakeholders
Effective delivery depends on whether the audience perceives both the message and its source as credible. CRA recently hosted a forum to discuss the importance...